Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.68 USD Market Closed
Market Cap: 75.7m USD

AVTE's latest stock split occurred on Apr 29, 2025

The company executed a 1-for-35 stock split, meaning that for every 35 shares held, investors received 1 new share.

The adjusted shares began trading on Apr 29, 2025. This was the only stock split in AVTE's history.

Last Splits:
Apr 29, 2025
1-for-35
Pre-Split Price
91.4 2.68
Post-Split Price
N/A
Before
After
Last Splits:
Apr 29, 2025
1-for-35

Aerovate Therapeutics Inc
Stock Splits History

AVTE Stock Splits Timeline
Apr 29, 2025
Apr 29, 2025
Split 1-for-35
/0.028571428571429
Pre-Split Price
91.4 2.68
Post-Split Price
N/A
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.143 0.143 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.4 8.4 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
3.5 3.5 EUR N/A
Load More

Aerovate Therapeutics Inc
Glance View

Market Cap
75.7m USD
Industry
Biotechnology

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.

AVTE Intrinsic Value
Not Available
Back to Top